Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by Sailboatdreamon Jun 09, 2022 8:20am
154 Views
Post# 34742859

RE:RE:RE:RE:RE:RE:Meanwhile Verte 's IR department

RE:RE:RE:RE:RE:RE:Meanwhile Verte 's IR departmentWe all have our investment styles and strategies.

back to the issues at hand:

-buyer paid $1.57.  Sernova management unable to sustain that level

-many of us have been "misled" by management

-I don't many short term catalysts left.  So I guess patience is in order.  Perhaps the second tranche of Evotec purchase in August will create some momentum

-I also see glaring issues with governance.  This is a one man show.  BoD absolutely not independent.  No one has shareholders interests in mind.  If Chris could replace all retail shareholders with 2 or 3 institutionals, he would.  But of course he has not shown he has the competence to do this

this is turning out to be a difficult relationship.  Management unhappy with retail investors.  Investors not seeing the return they are expecting given the stagnation between 2006 and 2021... and the level of risk.

the Last few weeks were meant to provide an "off ramp" to retail investors.  But management was unable to put the right conditions / sequence of events in place.

Amateur hour should be over by now.
<< Previous
Bullboard Posts
Next >>